検索結果 - Matko Kalac

  • 検索結果 1 - 5 結果 / 5
結果の絞り込み
  1. 1
    Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

    Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma 著者: Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Ellen Neylon, Paul Johannet, Ying Wei, Jasmine Zain, Owen A. O’Connor

    出版事項 2013
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  2. 2
    Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

    Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma 著者: Matko Kalac, Salvia Jain, Constantine S. Tam, Zhengrui Xiao, Francesca Montanari, Jennifer A. Kanakry, Bryan D. Huber, Mendel Goldfinger, Owen A. O’Connor, Enrica Marchi

    出版事項 2023
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  3. 3
    HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

    HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL 著者: Matko Kalac, Luigi Scotto, Enrica Marchi, Jennifer E. Amengual, Venkatraman Seshan, Govind Bhagat, Netha Ulahannan, Violetta V. Leshchenko, Alexis M. Temkin, Samir Parekh, Benjamin Tycko, Owen A. O’Connor

    出版事項 2011
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  4. 4
    A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

    A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma 著者: Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine E. Atkins, Aishling M. Rada, Hye A. Kim, Codruța Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, Mark A. Francescone, Lawrence Schwartz, Serge Cremers, Owen A. O’Connor

    出版事項 2017
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  5. 5
    Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

    Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial 著者: Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas, Jennifer E. Amengual, Changchun Deng, Matko Kalac, Lorenzo Falchi, Enrica Marchi, Ithamar Turenne, Renee Lichtenstein, Celeste Rojas, Mark Francescone, Lawrence H. Schwartz, Bin Cheng, Kerry J. Savage, Diego Villa, Michael Crump, Anca Prica, Vishal Kukreti, Serge Cremers, Joseph M. Connors, John Kuruvilla

    出版事項 2017
    全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: